Rigetti Computing, Inc.
Full-stack quantum hardware + cloud-access (QCS, Amazon Braket, Azure Quantum), on-premises QPU system sales (Novera 9Q → 108Q), and foundry/government R&D contracts; pre-commercial, government-revenue-concentrated, equity-funded.
The thesis on this name
State of Quantum Computing
Among the speculative cohort, Rigetti has a defensible structural story: owns its fab (faster iteration), a shipping commercial QPU (Novera), real national-lab traction, and a clean balance sheet (zero debt, $569M cash) to survive the pre-revenue valley. Best expressed LONG vs a weaker modality (QBTS) rather than naked. Superconducting also benefits from the broadest ecosystem tooling support (CUDA-Q, etc.).
State of Quantum Computing
Long leg of an RGTI/QBTS modality pair — superconducting full-stack with captive fab, $569M cash, zero debt, shipping Novera QPU; expresses 'superconducting > annealing-with-a-late-gate-pivot'.
State of Quantum Computing
Long leg of an RGTI-vs-QBTS relative-value pair, NOT a standalone conviction long. $569M cash, zero debt, $100M CHIPS LOI, Novera QPU + national-lab traction, real superconducting roadmap with a clearer fault-tolerance path than annealing. Pair structure neutralizes the shared sector-beta/bubble risk so the position expresses 'superconducting full-stack > annealing-with-a-gate-pivot' rather than a naked momentum long.
Earnings, margins, COGS & capex
Pre-commercial: FY2025 revenue $7.1M (down 34% YoY, ~90% government), gross profit ~$2.1M (~30% margin), operating loss $(84.7)M, GAAP net loss $(216.2)M (warrant-remeasurement-inflated). Q1 FY26 revenue $4.4M (+198% off a $1.5M base), gross profit $1.4M, operating loss $(26.0)M, non-GAAP net loss $(14.7)M; GAAP net income $33.1M was a non-cash warrant gain. The balance sheet is the story: $569.0M cash + investments, $0 debt.
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~69¢ is cost of goods and ~6¢ operating expense, leaving ~25¢ of operating profit.
Revenue trend
Margins
thin and volatile on a tiny revenue base
deeply negative, widening in absolute dollars
COGS structure
Q1 FY26 cost of revenue $3.0M (on $4.4M revenue) — hardware/foundry/cloud-delivery COGS; gross profit ~$1.4M
Capex
Captive Fab-1 foundry + cryo test infrastructure; exact capex not separately disclosed in releases reviewed — not disclosed
Latest earnings
Revenue $4.4M beat the prior-year $1.5M; quantum pure-plays trade on milestones not EPS — non-GAAP net loss $(14.7)M roughly in line. Q4 FY25 revenue ($1.9M) had missed forecasts.
No formal revenue guidance; guidance is roadmap-based — 150+ qubits at 99.7% fidelity by late 2026, 1,000+ qubits by end-2027
- Cash + investments (Q1 FY26)
- $569.0M
- Debt
- $0
- R&D (Q1 FY26)
- $20.0M
- SG&A (Q1 FY26)
- $7.4M
- Operating loss (Q1 FY26)
- $(26.0)M
- Non-GAAP net loss (Q1 FY26)
- $(14.7)M
- Diluted shares (Q1 FY26)
- ~335.4M
- Largest system
- 108-qubit Cepheus-1-108Q (99.0-99.8% 2-qubit fidelity)
- Government revenue share (FY2025)
- 90.2%
Growth drivers
- Government / sovereign quantum program funding (US DoC $100M, UK up-to-$100M, AFRL/AFOSR)
- On-prem Novera QPU system sales to national labs and quantum centers
- Cloud-access usage as qubit count/fidelity rises (Braket, Azure, QCS, qBraid)
- Quanta + NVIDIA partnerships (manufacturing scale + hybrid HPC-quantum)
- Roadmap milestones (150Q → 1,000Q) unlocking larger contracts if hit
Reported financials — SEC EDGAR
Audited GAAP figures pulled from SEC filings · latest filing 2026-03-04. The audited primary-source spine — not financial advice.
Revenue — annual (GAAP)
Margins & balance sheet — FY’25
Bull & bear
A cash-fortified, vertically-integrated superconducting pure-play with a credible scaling roadmap, blue-chip cloud distribution, a strategic Quanta partnership, and government tailwinds — optionality on quantum advantage with no near-term financing risk.
- Fortress balance sheet: $569.0M cash + investments and $0 debt (Q1 FY26), built via ATM sales + warrant exercises; multi-year runway at the current ~$60-85M/yr opex burn removes the going-concern risk that historically dogged Rigetti.
- Real technical progress: launched 108-qubit Cepheus-1-108Q (twelve 9-qubit chiplets — the industry's largest modular superconducting system) into general availability across QCS, Amazon Braket, Azure Quantum and qBraid, at 99.0-99.8% median two-qubit gate fidelity.
- Vertical integration via captive Fab-1 (Fremont): the first dedicated quantum IC foundry gives faster design-iteration cycles, supply-chain control, and a foundry-services/government revenue line (AFRL, AFOSR awards).
- Strategic validation + distribution: Quanta Computer collaboration (each to invest $100M+ over 5 years; Quanta took a $35M equity stake); hardware live on AWS Braket and Azure Quantum; Novera on-prem QPUs ship to national labs/universities (e.g. University of Saskatchewan).
- Government + sovereign-compute tailwinds: 90%+ of revenue is government; a $100M US Department of Commerce quantum agreement and a planned up-to-$100M UK investment (1,000+ qubit system in 3-4 years) position it as a Western superconducting champion.
- Roadmap is concrete and dated: 150+ qubits at 99.7% fidelity by late 2026 and 1,000+ qubits by end-2027 — milestones that would re-rate the equity from optionality to early commercialization.
A pre-commercial science project trading at a ~800x sales multiple: revenue is tiny and shrank in 2025, losses are widening, the business runs on dilution, insiders are net sellers, and the path to quantum advantage (and any cash-flow) remains years out and uncertain.
- Revenue is minuscule and went backwards: FY2025 revenue fell 34% to $7.1M (from $10.8M in 2024), ~90% from lumpy government contracts. The Q1 FY26 '+198%' is off a $1.5M base and reflects contract timing, not durable commercial demand.
- Valuation is in bubble territory: ~$6.1B market cap on $7.1M trailing revenue is a ~800x+ P/S; the equity prices in quantum advantage no one has achieved. The stock round-trips violently (52-week range $10.80-$58.15).
- Losses are large and widening: FY2025 operating loss $(84.7)M and GAAP net loss $(216.2)M (inflated by non-cash warrant remeasurement, which also makes Q1 FY26 'GAAP net income' of $33.1M misleading — the true non-GAAP net loss was $(14.7)M).
- The business model is dilution: the $569M cash pile was raised by selling stock. Diluted shares rose from ~302M (Q1 FY25) to ~335M (Q1 FY26) and will keep rising, capping per-share upside.
- Insider behavior is a red flag: ~$71.5M of net insider selling over two years and zero insider buying — management is monetizing the rally, not adding.
- Formidable, better-capitalized competition: IBM, Google, Amazon (in-house superconducting) plus IonQ (trapped-ion, ~$130M FY25, ~18x Rigetti) and D-Wave. Sub-scale on revenue; existential risk a rival modality or hyperscaler wins. Not selected for DARPA QBI Stage B.
- Quantum advantage timeline risk is binary and long-dated: 1,000+ qubit / fault-tolerance goals are end-2027+; if error-correction or scaling stalls, there is no fallback cash-generative business.
What it is worth
Multiple-based (EV/Sales) cross-check + scenario/optionality framing — DCF is not meaningful pre-revenue-scale; the equity is a real option on quantum advantage
If a roadmap milestone slips or quantum-winter sentiment returns, an ~800x P/S compresses hard. A re-rate to even 100-200x forward sales implies substantial downside; the 52-week low of $10.80 (vs ~$18.36) shows the realized drawdown range.
At ~$6.1B market cap on $7.1M FY25 revenue, RGTI trades at ~800x+ trailing P/S — far above IonQ (~50-100x) and the broader quantum cohort. Current fundamentals can't support a 'fair' base; the price embeds successful execution of the 1,000-qubit roadmap. Base case = roughly current-to-modestly-lower while milestones are awaited.
Hitting 150Q (late-2026) at 99.7% fidelity with visibility to 1,000Q (2027), plus a first commercial quantum-advantage use case, could justify a multi-billion-dollar step-up. Bull anchors on revenue inflecting toward IonQ-scale ($100M+) within 2-3 years.
Valuation is execution- and sentiment-driven, not cash-flow-supported. The $569M net cash (~$1.70/share of the ~$18 price) is a floor; the rest is option value on milestones. Method: relative EV/Sales vs. IonQ/D-Wave + binary-milestone optionality, NOT asserted intrinsic value.
SWOT
Strengths
- $569M net cash, $0 debt — multi-year runway, no near-term financing risk (Q1 FY26)
- Vertical integration via captive Fab-1 quantum IC foundry (Fremont)
- Modular chiplet architecture: 108-qubit Cepheus-1-108Q, 99.0-99.8% 2-qubit fidelity
- Distribution via AWS Braket, Azure Quantum, qBraid + on-prem Novera QPU sales
- Strategic Quanta Computer partnership ($100M+ each / 5yr, $35M equity stake)
Weaknesses
- Tiny revenue ($7.1M FY25) down 34% YoY; ~90% government-concentrated and lumpy
- Deep operating losses ($84.7M FY25) with no line of sight to breakeven
- Funded by continuous equity dilution (share count 302M→335M YoY)
- GAAP results distorted by non-cash warrant remeasurement
- Not selected for DARPA QBI Stage B
Opportunities
- National quantum programs / sovereign compute: US DoC $100M + up-to-$100M UK investment
- Roadmap milestones (150+ qubits late-2026, 1,000+ end-2027) would re-rate the equity
- Quantum-AI / HPC hybrid demand (NVIDIA, Quanta)
- Foundry/QPU-as-a-product sales to national labs and quantum centers
- First commercially useful quantum-advantage application unlocks a large TAM
Threats
- Hyperscalers (IBM, Google, Amazon, Microsoft) with vastly larger R&D budgets, same modality
- Alternative-modality pure-plays winning (IonQ trapped-ion ~18x revenue; neutral-atom, photonic)
- Multiple compression — ~800x P/S acutely sensitive to roadmap slip or quantum-winter sentiment
- Quantum-advantage / fault-tolerance may arrive years late or via a different architecture
- Insider net selling + retail-driven volatility
Moats, dependencies & bottlenecks
Moats
First dedicated quantum chip fab — design-iteration speed + supply control + foundry-services revenue; capital-intensive and replicable by larger players.
Differentiated scaling approach vs. monolithic chips; unproven that it wins the fault-tolerance race.
Incumbency in Western quantum programs; contract-renewal-dependent and politically exposed.
Distribution shared with competitors on the same marketplaces; low switching costs pre-commercial.
Dependencies
Operations funded by selling stock, not revenue; depends on a high share price persisting.
customer-concentration Revenue collapses if program funding is cut or a major contract is not renewed; lumpy/timing-driven.
strategic-partner Capital and manufacturing-scale support concentrated in one non-US partner; subject to regulatory clearance.
Bluefors) Specialized, few-supplier inputs; lead-time and single-vendor exposure.
1,000Q end-2027) The entire valuation rests on hitting dated fidelity/scale milestones.
Bottlenecks
- Qubit fidelity at scale — pushing 2-qubit gate fidelity from ~99.0-99.8% toward the error-correction threshold while adding qubits
- Error correction / fault tolerance — no clear logical-qubit-overhead solution yet — the bottleneck between demonstration and commercially useful quantum advantage
- Commercial demand beyond government — ~90% government revenue means the missing piece is repeatable enterprise use cases
- Capital efficiency: $60-85M/yr opex burn vs <$10M revenue forces perpetual dilution
- Cryogenic + interconnect scaling — wiring, control electronics, and chiplet interconnect fidelity at 1,000+ qubits are unsolved
Top signals & trends
Top signals
Chiplet scaling thesis executing on schedule
Removes near-term going-concern / financing risk
No durable commercial demand; contract-timing-driven and lumpy
Prices in quantum advantage not yet achieved
Management monetizing the rally
External validation + government funding tailwind
Competitive-process setback vs. better-funded modalities
Headline 'profit' is an accounting artifact
Trends
Funds Rigetti as a Western superconducting champion; up-to-$100M UK + $100M DoC
NVIDIA/Quanta partnerships position it in the HPC-quantum stack
Enabled the cash raise via a high share price, but creates ~800x P/S froth and crash risk
Better-funded incumbents compress Rigetti's odds of winning
150Q (late-2026) and 1,000Q (end-2027) are binary catalysts
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
Atomic-layer-etch and cryogenic process tools for qubit manufacturing at Fab-1 (non-US; ANALYSIS)
Dilution refrigerators / cryogenic systems for superconducting QPUs (private, Finland; ANALYSIS)
GPU/CUDA-Q hybrid compute + classical co-processing for error decoding
Optical-interconnect / quantum-networking collaborator (AFRL $5.8M contract); private, Netherlands (ANALYSIS)
Quantum error-correction (decoder) software partner; private, UK (ANALYSIS)
Dept. of Commerce, DARPA) ~90% of revenue — foundry-services, R&D awards, $100M DoC agreement; DARPA QBI Stage A
Target for up-to-$100M UK investment and 1,000+ qubit system (non-US; ANALYSIS)
On-prem 9-qubit Novera QPU buyer (academic channel; non-US; ANALYSIS)
Cloud-access customers reach Rigetti QPUs via Braket
Cloud-access customers via Azure Quantum
Largest pure-play by revenue (~$130M FY25, ~18x Rigetti) on trapped-ion; better capitalized, commercially further along
Quantum-annealing pure-play (~$24.6M FY25 revenue, 83% gross margin); competes for the same investor capital
Same superconducting modality at vastly larger scale + R&D budget
Superconducting (Willow); hyperscaler resources and error-correction leadership
Both Rigetti's distribution channel AND a quantum-hardware competitor
Distribution partner and topological-qubit competitor (Majorana 1)
Photonic pure-play, sub-scale; competes for retail-quantum capital
Trapped-ion leader on fidelity/volume; Honeywell-backed, filed toward IPO (private; ANALYSIS)